404
Gene Therapy Market Report
The Gene Therapy Market is Segmented by Vector Type (Non-Viral Vectors, Viral Vectors ), by Indication Type (Neurological Diseases, Cancer, Hepatological Diseases, Duchenne Muscular Dystrophy, and Others), by Delivery Method Type (In Vivo Gene Therapy, Ex Vivo Gene Therapy), and by Region (North America, Europe, Asia-Pacific, and Rest of the World)
The Gene Therapy Market is Segmented by Vector Type (Non-Viral Vectors, Viral Vectors ), by Indication Type (Neurological Diseases, Cancer, Hepatological Diseases, Duchenne Muscular Dystrophy, and Others), by Delivery Method Type (In Vivo Gene Therapy, Ex Vivo Gene Therapy), and by Region ...
Enquiry Form
Gene Therapy Market is likely to witness an impressive CAGR of 27.8% during the forecast period. The prime factors contributing to the growth of the market are rising incidences of cancer, and other chronic diseases, availability of reimbursements, and increasing approvals and launches of new products.
Gene Therapy Market - Snapshot |
|
Growth |
27.8% for the next five years |
Fastest-Growing Indication Type |
Cancer |
Major Vector Type |
Non-Viral Vectors |
Region with the highest demand |
North America |
Key Players |
Biogen, Inc., Novartis International AG, Gilead Sciences, Inc., Spark Therapeutics, Inc., MolMed S.p.A., Orchard Therapeutics plc., Sibiono GeneTech Co. Ltd., Shanghai Sunway Biotech Co., Ltd., Bluebird Bio, Human Stem Cells Institute PJSC, AnGes MG, Inc., Alnylam Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., Jazz Pharmaceuticals, Inc., Akcea Therapeutics, and Dynavax Technologies Corporation |
Wish to Get a Free Sample? Register Here
Based on the indication type, the gene therapy market is segmented as neurological diseases, cancer, duchenne muscular dystrophy, heptological, and others. The cancer segment is expected to experience the highest growth in the market during the forecast period. This growth can be attributed to the approval of a growing number of gene therapies for the treatment of cancer and the rising incidences of hematologic cancers.
Based on the vector type, the market is segmented as non-viral and viral vectors. The non-viral vectors’ segment has been further bifurcated into oligonucleotides and others; and the viral vectors’ segment has been further bifurcated into retroviral vectors, adeno-associated virus vectors, and others. The non-viral vectors’ segment is expected to grow at a higher rate over the forecast period, owing to the higher market penetration of oligonucleotide-based non-viral vector gene therapies.
In terms of regions, North America is estimated to be the largest market during the forecast period with lucrative growth opportunities. This growth can be attributed to the presence of major players, rising prevalence of chronic diseases, high and increasing healthcare expenditure, presence of advanced healthcare infrastructure, and availability of reimbursements. Europe and Asia-Pacific are also expected to offer substantial growth opportunities during the forecast period.
Know which region offers best growth opportunities. Register Here
Some of the major players in the gene therapy market are Biogen, Inc., Novartis International AG, Gilead Sciences, Inc., Spark Therapeutics, Inc., MolMed S.p.A., Orchard Therapeutics plc., Sibiono GeneTech Co. Ltd., Shanghai Sunway Biotech Co., Ltd., Bluebird Bio, Human Stem Cells Institute PJSC, AnGes MG, Inc., Alnylam Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., Jazz Pharmaceuticals, Inc., Akcea Therapeutics, and Dynavax Technologies Corporation.
Gene therapy is a technique which uses the introduction of DNA into a patient’s body in order to treat or prevent a disease. A functioning gene is present in the introduced DNA, to correct the effects of a disease, which causes mutations. This therapy aims at reestablishing normal function and involves repairing, repressing, or replacing dysfunctional genes that cause disease. Gene therapy:
This report studies the market covering a period of 12 years of trend and forecast. The report provides detailed insights into the market dynamics to enable informed business decision making and growth strategy formulation based on the opportunities present in the market.
Gene Therapy Market Research Report - Features |
|
Market Segmentation |
4 |
Regions Covered |
4 |
Countries/Sub-Regions Covered |
17 |
No. of Figures & Tables |
>150 |
Company Profiles |
10 |
The gene therapy market is segmented into the following categories.
Want to know the most attractive market segments? Register Here
This report offers high-quality insights and is the outcome of detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact book, press release, journals, investor presentation, white papers, patents, and articles have been leveraged to gather the data. We conducted more than 10 detailed primary interviews with the market players across the value chain in all four regions and with industry experts to obtain both the qualitative and quantitative insights.
This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision making for the existing market players as well as those willing to enter the market. The following are the key features of the report:
With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:
Company Profiling
Market Segmentation
Competitive Benchmarking
Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].
The gene therapy market is expected to witness an impressive growth of 27.8% CAGR in the foreseeable future.
Biogen, Inc., Novartis International AG, Gilead Sciences, Inc., Spark Therapeutics, Inc., MolMed S.p.A., Orchard Therapeutics plc., Sibiono GeneTech Co. Ltd., Shanghai Sunway Biotech Co., Ltd., Bluebird Bio, Human Stem Cells Institute PJSC, AnGes MG, Inc., Alnylam Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., Jazz Pharmaceuticals, Inc., Akcea Therapeutics, and Dynavax Technologies Corporation are among the key players in the gene therapy market.
North America is expected to remain the largest gene therapy market during the next five years.
The cancer segment is expected to experience the highest growth in the gene therapy market in the coming years.
Billing Information
404
We are sorry, Page not found!
The page you are looking for might have been removed had its name changed or is temporarily unavailable.
Back To HomepageMarket Research Reports | Consulting | Insights | Blog | Conferences | Careers | Subscribe | Sitemap | XML
Disclaimer | T&C - Privacy Policy | Cookies | Unsubscribe
© Copyright 2019 Stratview Research. Trademark of Radiant Offshore Consultancy LLP. All Rights Reserved.
Don't want insights worth $20,000 for free?
Give it a Thought!
We are offering insights worth more than $20,000 for Free! Only for registered users.
You will get access to :
Decision Makers / CXO Level Professionals from leading organizations have already started registering!
You can cancel your registration anytime with a single click